On April 29, 2025 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, reported that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences (Press release, In8bio, APR 29, 2025, View Source [SID1234652311]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth of data we’re presenting at upcoming medical conferences reflects the scientific rigor and clinical potential of IN8bio’s gamma-delta T cell platform," said William Ho, CEO and co-founder, IN8bio. "From our INB-200/400 program in newly glioblastoma to our novel T cell engager technologies, we are expanding the therapeutic applications of this unique class of therapies. These presentations highlight IN8bio’s capabilities, know-how in manufacturing, and the clinical potential of our programs to help patients with significant unmet needs across oncology and immune-mediated diseases."

Upcoming presentations:

American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2025

Poster Title: A novel gamma-delta T cell engager platform for cancer immunotherapy
Abstract Presentation Number: 7321 (Poster Board 7)
Session Title: Immunology/T Cell Engagers and Novel Antibody-Based Therapies
Date/Time: Wednesday, April 30, 2025, 9:00 – 12:00 PM CDT
Location: McCormick Place Convention Center, Chicago, IL
More information: www.aacr.org/meeting/aacr-annual-meeting-2025/abstracts.

International Society for Cell & Gene Therapy (ISCT) 2025

Oral Presentation Title: From Donor to Therapy: How Robust Manufacturing Shapes the TCR Repertoire and Cytotoxic Power of Donor-Derived Allogeneic ex vivo Expanded and Activated γδ T Cell Products*
Date/Time: Friday, May 9, 2025, 3:00 – 4:00 PM CDT
Presenter: Mariska ter Haak, Senior Director Analytical Development, IN8bio
Session: Oral Abstract Session – Immunotherapy (CAR-T, T Reg, NK Cells etc.)
*Host Region (US East) Abstract Award

Poster Presentation Title: Selection and Implementation of the Electronic Quality Management System for High Complexity Clinical Stage Cellular Therapy Company
Date/Time: Thursday, May 8, 2025, 6:00 – 7:30 PM CDT
Presenter: Guoling Chen, Senior Director of Quality Operations, IN8bio
More information: View Source

American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2025 Conference

Poster Presentation Title: INB-600: A Novel T Cell Engager Platform Specific for gamma-delta (γδ) T cells
Date/Time: Thursday, May 15, 2025, Time: 5:30 – 7:00 PM CDT
Presenter: Lawrence Lamb, Ph.D., Co-Founder and Chief Scientific Officer, IN8bio
Location: Poster Hall I2, New Orleans Ernest N. Morial Convention Center

Oral Presentation Title: Decoding the Molecular Signature of Expanded Gamma-delta T Cell Products; TCR and Immune Gene Expression from Allogeneic derived Products
Title: Molecular and Cellular Methods – Applications
Date/Time: Saturday, May 17, 2025, 10:30 – 10:45 AM CDT
Presenter: Mariska ter Haak, Senior Director Analytical Development, IN8bio
Location: NOLA Theater B, New Orleans Ernest N. Morial Convention Center
More information: View Source

American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2025

Oral Presentation Title: INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ).
Presenter: Louis "Burt" Nabors, MD
Abstract #: 2007
Session: Central Nervous System Tumors
Session Type: Oral Abstract Session
Session Date and Time: May 30, 2025, 2:45 – 5:45 PM CDT
Presentation Time/Duration: 4:57 – 5:09 PM CDT
More information: View Source